In vivo Study in Minipigs Confirmed Systemic Safety and No Genotoxicity of ATx201
COPENHAGEN, MARCH 22, 2016 – AntibioTx detected no systemic availability of ATx201 after the application in Hanford minipigs. The study protocol consisted of applying ATx201 twice a day for 28-days, followed […]
AntibioTx Rewarded Grant Funding to Conduct Phase 1 and Phase 2 Studies in Atopic Dermatitis Patients
COPENHAGEN, OCTOBER 26, 2015 – AntibioTx has been rewarded grant funding from The Innovation Fund Denmark to further develop a candidate developed on the basis of extensive compound screening models. […]